Verona Pharma plc
VRNA
Hisse Senetlerindeki Sıralama
#2227
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Hisse Fiyatı
$106.91
Son senkronizasyon: 2025-10-07
Piyasa Değeri
$9.09B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
GB
Ticaret Verona Pharma plc (VRNA)
Kategori
Healthcare
Verona Pharma plc (VRNA) için P/B oranı
October 2026 itibarıyla P/B oranı TTM: 41.96
Verona Pharma plc şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 41.96'dir. 2023 yılının sonunda şirketin P/B oranı 6.02 idi.
Verona Pharma plc için P/B oranı geçmişi 2005 - 2026 arası
Her yılın sonunda P/B oranı
| Yıl | P/B Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 41.96 | 130.17% |
| 2024 | 18.23 | 202.67% |
| 2023 | 6.02 | -19.60% |
| 2022 | 7.49 | 178.89% |
| 2021 | 2.69 | 115.77% |
| 2020 | 1.24 | -3.18% |
| 2019 | 1.29 | 3.29% |
| 2018 | 1.24 | 34.11% |
| 2017 | 0.93 | -13.81% |
| 2016 | 1.08 | -61.46% |
| 2015 | 2.79 | 192.12% |
| 2014 | 0.96 | -53.11% |
| 2013 | 2.04 | 34.88% |
| 2012 | 1.51 | 42.73% |
| 2011 | 1.06 | -15.01% |
| 2010 | 1.25 | 40.84% |
| 2009 | 0.89 | -26.97% |
| 2008 | 1.21 | 33.07% |
| 2007 | 0.91 | 31.45% |
| 2006 | 0.69 | -80.59% |
| 2005 | 3.57 | 0.00% |
Benzer şirketler veya rakipler için P/B oranı
| Şirket | P/B Oranı | P/B Oranı Farkı | Ülke |
|---|---|---|---|
| 6.251 | -85.10% |
US
|
|
| 13.2547 | -68.41% |
US
|
|
| 4.208 | -89.97% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -85.27% |
NL
|
